RUDN Journal of Agronomy and Animal Industries (Jun 2022)

Use of recombinant interleukin-2 in traumatic disease in veterinary medicine

  • Oksana A. Gizinger

DOI
https://doi.org/10.22363/2312-797X-2022-17-2-210-220
Journal volume & issue
Vol. 17, no. 2
pp. 210 – 220

Abstract

Read online

Тhe article presents analysis of current information on the possibility of using recombinant interleukin-2 in traumatic disease in veterinary medicine. The analysis included publications from the following databases - P ubMed, MedLine, BIOSIS, ToxiNet, CANCERLIT, CINAHL, CISCOM, EMBASE, International Pharmaceutical Abstracts, and NAPRALERT, using 10 keywords and their combinations. It was shown that in trauma of any genesis, an immunodeficiency state occurs associated with an imbalance of Th1/Th2 cytokines. The use of recombinant interleukin-2 restores synthesis of endogenous interleukin-2, provides adequate targeted drug correction of immune dysfunctions, increasing the clinical and immunological effectiveness of therapeutic measures.

Keywords